Quote & Headlines
5d 1m 3m 1y 5y 10y
There are no Transcripts on ALPMY.
There are no News articles on ALPMY.
ALPMY vs. ETF Alternatives
Friday, Nov 13:29 PMAstellas reports Xtandi sales, Medivation rallies
Friday, Nov 13:29 PM| Comment!
- Astellas Pharma (ALPMY) reports H1 consolidated net sales ( ¥ millions) of ¥556,702, up 16.7% Y/Y.
- Net income ( ¥ millions) for H1 falls 16% Y/Y to ¥48.195. (full results)
- Xtandi U.S. sales of ~$190M for April-September. (supplementary documents)
- Backing out FQ1 sales of $82M gets ~$108M in U.S. Xtandi sales for FQ2.
- These numbers are likely behind the rally in shares of Medivation (MDVN +10.1%), Astellas' Xtandi partner.
Tuesday, Sep 247:05 AMTeva launches generic Adenoscan in U.S.|Tuesday, Sep 247:05 AM| Comment!
Thursday, Aug 13:40 PMXtandi sales weigh on Medivation
Thursday, Aug 13:40 PM| Comment!
- As reported here earlier, Astellas Pharma's (ALPMY.PK +1%) quarterly report showed Xtandi sales of $82M. That's short of consensus and bad news for partner Medivation (MDVN -1.3%).
- More color: William Blair's forecast was for sales of $85.2M (so a big miss there) — Astellas' full year Xtandi sales guidance of $400M is well below the firm's estimate of $459M.
Thursday, Aug 11:49 PMAstellas Pharma confirms interim analysis of Xtandi study to occur this year
Thursday, Aug 11:49 PM| Comment!
- Astellas Pharma (ALPMY.PK +1.2%) corrects a translation error in its FQ1 conference call earlier, confirming that interim analysis on its Prevail study of Xtandi will actually occur this year.
- The company became aware of an error in the English translation, which cited incorrect timing of the interim analysis.
- Guidance has not changed.
Thursday, Aug 18:21 AMAstellas reports, Xtandi sales in focus for Medivation
Thursday, Aug 18:21 AM| Comment!
- Astellas Pharma (ALPMY.PK) reports FQ1 consolidated net sales of ¥275.8B (.pdf), up 13.4% Y/Y.
- Net sales of Xtandi — the prostate cancer treatment developed and commercialized with partner Medivation (MDVN) — were $82M for the period, below Street estimates of $83.7M. (supplemental documents)
- Xtandi faces what some say is looming threat from Janssen's acquisition of Aragon and the company's ARN-509.
Wednesday, Jul 3111:24 AMAstraZeneca signs collaboration deal with Fibrogen to develop anemia drug
Wednesday, Jul 3111:24 AM| Comment!
- AstraZeneca (AZN +0.9%) inks a collaboration deal to develop an oral anemia drug with privately held U.S. biotechnology company FibroGen that could potentially be worth more than $815M.
- The collaboration includes the development and commercialization of FG-4592, a drug that mimics the body's response to being at high altitude, which stimulates production of red blood cells and would be used to treat anemia.
- AZN's is making an initial $350M payment to FibroGen, will could rise to as much as $815M if development milestones are reached, and possibly even exceed that with royalty payments on future sales in the low 20% range.
- AZN has made $2.8B worth of acquisition and collaboration deals in the last six months alone in a bid to counteract the revenue-sapping effect of generic competition.
- The deal is limited to the U.S., China and a few other markets, but excludes Europe, Japan and other markets where FibroGen already has an agreement with Astellas Pharma (ALPMY.PK).
Wednesday, Jun 269:05 AMMedivation (MDV) and Astellas (ALPMF.PK) enroll the first patient in a Phase II trial for enzalutamide, a treatment for triple-negative breast cancer, for which "there are no approved targeted therapies." The trial will recruit approximately 80 patients, who will take enzalutamide orally once a day. (PR) |Wednesday, Jun 269:05 AM| Comment!
Tuesday, Jun 258:18 AMCytokinetics (CYTK +9.8%) grants Astellas (ALPMF.PK) an exclusive license to co-develop and commercialize Cytokinetics' CK-2127107 treatment for muscle weakness, which is in Phase I trials. Cytokinetics will receive $16M up front and is eligible to receive over $24M in reimbursements during the first two years. Astellas could also pay $450M in R&D and sales milestones and royalties, as well as make other milestone payments. (8-K) |Tuesday, Jun 258:18 AM| Comment!
Monday, Jun 38:06 AM
Wednesday, May 298:05 AMAmgen (AMGN -0.6%) forms a JV with Japan's Astellas Pharma (ALPMF.PK) to develop and sell five new drugs in the latter's home country, with the hope being to launch the first medicine in 2016. The JV should help Amgen partly fill what it has described as "a noticeable gap" - its absence from China and Japan. (PR) |Wednesday, May 298:05 AM| Comment!
Friday, May 247:58 AM
Thursday, May 236:21 PMAVEO Pharmaceuticals (AVEO) has been informed by its partner, Astellas Pharma (ALPMY.PK), that it no longer intends to submit a Marketing Authorization Application to the European Medicines Agency for tivozanib, its treatment for advanced renal cell carcinoma, nor does not intend to fund any future trials under its strategic collaboration agreement. AVEO says it's evaluating the impact of the news and its options for the drug going forward. AVEO -14.7% AH. |Thursday, May 236:21 PM| Comment!
Monday, May 138:44 PMJapanese stocks move higher in early trading after a record finish for the S&P 500 overnight. The Nikkei Average gained 0.3% to 14,822, extending its gains after finishing at its highest level yesterday since December 2007. Big gainers include: Hino Motors (HINOY.PK +2.2%), Isuzu Motors (ISUZY.PK +1.7%) and Astellas Pharma (ALPMY.PK +3.9%). |Monday, May 138:44 PM| 1 Comment
Monday, May 135:09 PMShares of Optimer Pharmaceutical (OPTR +14%) ramped up into the close on reports that AstraZeneca (AZN), Astellas Pharma (ALPMY.PK) and Cubist Pharmaceuticals (CBST) are among the first round bidders for the antibiotic manufacturer. OPTR disclosed almost three months ago that they were working with Centerview Partners and JPMorgan to explore its strategic options, including a potential sale. |Monday, May 135:09 PM| Comment!
Friday, Aug 312012, 2:22 PMThe FDA has given early approval to enzalutimide, a new prostate-cancer drug developed jointly by Medivation (MDVN +1.4%) and Astellas Pharma (ALPMY.PK). The drug - which was approved to treat men with prostate cancer that has spread or returned after prior treatment with another drug, docetaxel - will be sold under the brand name Xtandi. Dendreon (DNDN -0.6%), whose already struggling with lagging sales of its own prostrate drug, Provenge, trades down on the news. |Friday, Aug 312012, 2:22 PM| Comment!
Friday, Aug 32012, 5:42 PM